Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE vs EPANED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.
Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Treatment of frequent heartburn (FDA-approved for over-the-counter use),Gastroesophageal reflux disease (GERD),Erosive esophagitis,Duodenal ulcer,Gastric ulcer,Zollinger-Ellison syndrome,Helicobacter pylori eradication (as part of combination therapy)
Treatment of hypertension,Heart failure (adjunctive therapy with diuretics and digitalis),Asymptomatic left ventricular dysfunction (to reduce the risk of developing overt heart failure)
One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.
0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.
Magnesium hydroxide: not applicable (local action); omeprazole: 0.5-1 hour (terminal); sodium bicarbonate: not applicable (buffering agent). Omeprazole's half-life is short but pharmacodynamic effect (acid suppression) lasts ~24 hours due to covalent binding to proton pumps.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and 15-20 hours in severe impairment (Cr Cl <30 m L/min).
Omeprazole is extensively metabolized in the liver via CYP2C19 and CYP3A4; its metabolites are inactive. Magnesium hydroxide and sodium bicarbonate are not metabolized; they act locally and are partially absorbed. Sodium bicarbonate is converted to carbon dioxide and water via carbonic anhydrase.
Enalapril is extensively metabolized in the liver by ester hydrolysis to its active form, enalaprilat. No significant CYP450 metabolism.
Magnesium hydroxide: primarily fecal (unabsorbed magnesium), renal (absorbed magnesium); omeprazole: renal (~77% as metabolites) and fecal (~23%); sodium bicarbonate: renal (as bicarbonate or CO2).
Renal excretion of unchanged drug accounts for approximately 30-40% of elimination; biliary/fecal excretion accounts for 50-60% as metabolites and unchanged drug.
Magnesium hydroxide: negligible; omeprazole: 95% (albumin and alpha1-acid glycoprotein); sodium bicarbonate: negligible.
Approximately 85-90% bound to serum albumin.
Magnesium hydroxide: not applicable (local); omeprazole: 0.3-0.5 L/kg (extensive tissue distribution); sodium bicarbonate: 0.5-1 L/kg (total body water).
0.5-0.7 L/kg, indicating distribution primarily into extracellular fluid.
Magnesium hydroxide: not absorbed orally; omeprazole: 30-40% (oral, delayed-release formulation); sodium bicarbonate: 100% (oral, completely absorbed).
Oral: 70-80% due to first-pass metabolism; Intravenous: 100%.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of magnesium accumulation and sodium overload. For e GFR 30-59 m L/min/1.73m², reduce dose to one tablet every other day and monitor serum magnesium and sodium.
No adjustment required for renal impairment; drug is hepatically cleared.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce omeprazole dose to 10 mg (not available in this combination) or consider alternative; use with caution. Child-Pugh C: Contraindicated due to omeprazole accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider dose reduction by 75%.
Not recommended for use in pediatric patients (safety and efficacy not established).
0.2 mg/kg intravenously over 5 minutes every 2 hours; maximum single dose 20 mg.
Use with caution due to increased risk of electrolyte imbalance (hypermagnesemia, metabolic alkalosis) and renal impairment. Consider reducing dose to one tablet every other day. Monitor renal function and serum electrolytes.
Start at lower end of dosing range (0.1 mg/kg) due to potential for decreased hepatic function and increased sensitivity; monitor for QT prolongation.
None
FDA Warning: When pregnancy is detected, discontinue Epaned as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Long-term use (≥1 year) may increase risk of osteoporosis-related fractures; hypomagnesemia with prolonged PPI use; cyanocobalamin (vitamin B12) deficiency with long-term acid suppression; magnesium hydroxide may cause diarrhea; sodium bicarbonate may cause metabolic alkalosis, fluid retention, and worsen hypertension or heart failure; acute interstitial nephritis reported with PPIs; monitor renal function; interaction with clopidogrel (omeprazole reduces clopidogrel's active metabolite); increased risk of Clostridium difficile infection; avoid concurrent use of atazanavir or nelfinavir.
Angioedema (including laryngeal edema) risk; discontinue immediately and treat appropriately.,Hypotension in volume-depleted patients (e.g., those on diuretics or with heart failure).,Monitor renal function; risk of acute renal failure, especially in bilateral renal artery stenosis.,Hyperkalemia risk, especially in renal impairment, diabetes, or concomitant K+-sparing diuretics/supplements.,Cough (nonproductive, persistent) may occur.,Hepatic failure; rare but reported. Discontinue if jaundice or significant liver enzyme elevation occurs.
Hypersensitivity to any component; Concurrent use of rilpivirine-containing products; Severe renal impairment (Cr Cl <30 m L/min) due to risk of magnesium toxicity; Sodium-restricted diet (due to sodium content); Patients with metabolic alkalosis; Children under 12 years for over-the-counter use (varies by product).
Hypersensitivity to enalapril or any ACE inhibitor,History of angioedema related to previous ACE inhibitor therapy,Hereditary or idiopathic angioedema,Pregnancy (especially second and third trimesters),Concomitant use with aliskiren in patients with diabetes
Take on empty stomach; food reduces omeprazole absorption. Avoid high-fat meals. No known specific food interactions with antacid components.
No specific food interactions. Grapefruit juice does not affect palonosetron metabolism. Avoid alcohol consumption on chemotherapy days as it may worsen nausea or sedation.
First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is considered low risk; magnesium hydroxide can cause hypotonia and respiratory depression in neonates with prolonged use; sodium bicarbonate may lead to fluid overload or alkalosis.
Pregnancy category C. No adequate studies in pregnant women. In animal studies, no evidence of teratogenicity at clinically relevant doses. Risk of fetal harm cannot be ruled out. Use only if potential benefit justifies risk.
Omeprazole is excreted in breast milk in low amounts (M/P ratio ~0.5); magnesium hydroxide and sodium bicarbonate are poorly absorbed; considered compatible with breastfeeding, but monitor infant for diarrhea or electrolyte imbalance.
Not known if excreted in human milk. Caution advised. M/P ratio unknown.
No dose adjustment typically required; monitor for magnesium toxicity in renal impairment; consider reduced omeprazole dose if CYP2C19 polymorphisms present; sodium bicarbonate dose should be adjusted to avoid metabolic alkalosis.
No established dose adjustments for pregnancy. Pharmacokinetic changes in pregnancy are not well characterized; use lowest effective dose.
This combination uses sodium bicarbonate to rapidly raise gastric p H, enabling omeprazole absorption (enteric-coated omeprazole may be prematurely released; use non-enteric formulations). Magnesium hydroxide provides additional acid neutralization and a laxative effect. Avoid in patients with renal impairment (risk of magnesium toxicity, sodium overload). Administer on an empty stomach at least 1 hour before meals. Do not split or crush tablets.
EPANED (palonosetron) is a 5-HT3 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting (CINV). It has a longer half-life (~40 hours) than other agents in its class, allowing for single-dose protection. It is not effective for breakthrough nausea. Use caution in patients with electrolyte abnormalities or those taking other QT-prolonging drugs, as palonosetron does not significantly prolong QT interval at standard doses. Administer 30 minutes before chemotherapy. For dexamethasone-sparing regimens, consider single-dose palonosetron with dexamethasone.
Take this medication on an empty stomach at least 1 hour before a meal.,Swallow the tablet whole; do not crush or chew it.,Do not take with other antacids or calcium supplements.,Notify your doctor if you have kidney disease or are on a low-sodium diet.,Common side effects include diarrhea or stomach pain; report severe or persistent symptoms.,Avoid alcohol and NSAIDs as they can worsen stomach irritation.
Take this medication exactly 30 minutes before your chemotherapy session.,This drug prevents nausea and vomiting; it will not help if you already feel sick.,Common side effects include headache, constipation, or diarrhea; report persistent or severe symptoms.,Avoid driving or operating heavy machinery if you feel drowsy or dizzy after taking this medication.,Do not take any other anti-nausea medications without your doctor's approval.,Keep a diary of any vomiting episodes to share with your healthcare provider.
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE vs EPANED, answered by our medical review team.
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.. EPANED is a Vasopressor that works by Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE and EPANED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is: One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.. The standard adult dose of EPANED is: 0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE and EPANED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is . EPANED is classified as Category C. Pregnancy category C. No adequate studies in pregnant women. In animal studies, no evidence of teratogenicity at clinically relevant doses. Risk of fetal harm cannot be ruled out. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.